Ecopipam Treatment of Tourette Syndrome.
Phase of Trial: Phase I/II
Latest Information Update: 01 Oct 2015
At a glance
- Drugs Ecopipam (Primary)
- Indications Gilles de la Tourette's syndrome
- Focus Therapeutic Use
- Sponsors Psyadon Pharmaceuticals
- 28 Sep 2015 Status changed from discontinued to completed as per ClinicalTrials.gov record.
- 24 Jul 2012 Positive interim results from the phase II portion of this trial have been presented in a Psyadon Pharmaceuticals media release.
- 24 Jul 2012 Status changed from recruiting to discontinued (terminated early), according to a Psyadon Pharmaceuticals media release.